Compare Amphastar Pharmaceuticals Inc (AMPH) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

BRK.B trades at $495.49, up 0.37% on the day, with mixed technical signals showing a bearish overall trend but bullish moving averages. Analyst consensus is positive with 57% buy ratings, though key financial ratios are unavailable in the current dataset. The stock faces resistance near $497 and support at $492.

The outlook remains cautiously optimistic given strong analyst support, but the lack of recent fundamental data and bearish technical indicators suggest near-term volatility. Key risks include market sensitivity and execution challenges in Berkshire Hathaway's diverse holdings.